CN107349318A - A kind of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound and preparation method thereof - Google Patents
A kind of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound and preparation method thereof Download PDFInfo
- Publication number
- CN107349318A CN107349318A CN201710604800.8A CN201710604800A CN107349318A CN 107349318 A CN107349318 A CN 107349318A CN 201710604800 A CN201710604800 A CN 201710604800A CN 107349318 A CN107349318 A CN 107349318A
- Authority
- CN
- China
- Prior art keywords
- pericarpium trichosanthis
- extract
- longstamen onion
- onion bulb
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 43
- 239000008280 blood Substances 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 title claims abstract description 36
- 150000002632 lipids Chemical class 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000000284 extract Substances 0.000 claims abstract description 66
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 57
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 6
- 229960005305 adenosine Drugs 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229930003944 flavone Natural products 0.000 claims description 4
- 235000011949 flavones Nutrition 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 150000002213 flavones Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 210000004185 liver Anatomy 0.000 abstract description 16
- 241000699670 Mus sp. Species 0.000 abstract description 11
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000002079 cooperative effect Effects 0.000 abstract description 2
- 230000037356 lipid metabolism Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 244000078912 Trichosanthes cucumerina Species 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 4
- 229940126678 chinese medicines Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000975594 Trichosanthes rosthornii Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- -1 lipid compound Chemical class 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000009912 gualou xiebai baijiutang Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, it is active ingredient that the compound, which includes Pericarpium Trichosanthis extract and longstamen onion bulb extract, and the ratio of PERICARPIUM TRICHOSANTHIS and Longstamen Onion Bulb raw material is 1:7.83‑1:3.58.Pericarpium Trichosanthis extract, the blood lipid metabolism of hyperlipemia in mice can be improved after longstamen onion bulb extract and PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extract compatibilities, the PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extracts group of different proportion is better than the effect for adjusting blood fat that Pericarpium Trichosanthis extract or longstamen onion bulb extract is used alone.Illustrate that PERICARPIUM TRICHOSANTHIS plays cooperative effect with active component in Longstamen Onion Bulb, can preferably adjust blood fat, while the compound has significant antioxidation activity, and there is repair function to liver, initiative.
Description
Technical field
The invention belongs to the field of Chinese medicines, and in particular to one kind is main using Pericarpium Trichosanthis extract and longstamen onion bulb extract
The reducing blood lipid compound of composition.
Background technology
Modern society, with the change of the factors such as life style and environment, there occurs very big with the past for human diseases spectrum
Change, cardiovascular disease, which becomes, endangers one of major chronic disease of human health, and it is disorderly that hyperlipemia exacerbates metabolism
The risk of angiocardiopathy is disorderly added, hyperlipemia and its complication are considered as one of important social concern.High fat of blood
It is a kind of lifelong participation illness of Dyslipidemia.By drug therapy, blood fat can be stablized between normal value, but not by
Effect a radical cure.If stopping drug therapy, serum lipid concentrations can increase again.Western medicine regulating lipid is notable, but clinical observation is shown
The characteristics of it easily rebounds after having use, and curative effect is not easy to maintain, and exist and cause to side effects such as liver energy work(damages, so people couple
This some the psychology of fear.Therefore the functional food for developing not only efficient but also safe reducing blood lipid is necessary.
PERICARPIUM TRICHOSANTHIS is trichosanthes rosthornii Harms (Trichosanthesrosthornii Harms) or cucurbitaceous plant snakegourd
The pericarp of (Trichosanthes kirilowii Maxim) contains amino acids, flavonoids, triterpenes (Liu Jinna, Wen Chun
Show, Liu Ming, wait Snakegourd Fruits chemical composition and pharmacology activity research progress [J] Chinese medicines, 2013,36 (5):843-8.) etc. thing
There is expansion parteriole, anti-platelet aggregation, function promoting blood circulation and removing blood stasis, that alleviation is uncomfortable in chest (to come from old for matter, its extract or parenteral solution
New modest, Jin Youyu, soup light new pharmacologies [M] .17 version Beijing:People's Health Publisher, 2011.), have to angiocardiopathy
Certain therapeutic action.In Longstamen Onion Bulb active component promoting blood circulation and removing blood stasis be mainly saponin(e and adenosine class compound (come from Yao new lives, it is old
Seapeak, king are sharp Chinese medicines Longstamen Onion Bulb function of promoting blood circulation to disperse blood clots active matter Quality Research [C]:3rd world's combination of Chinese tradiational and Western medicine conference, in
Guangzhou Guangdong of state, 2007).Prevention and treatment of the PERICARPIUM TRICHOSANTHIS Longstamen Onion Bulb prescription to angiocardiopathy are significant, and safety, nothing
Toxic side effect (comes from Zou Chuncai, Yan Haiyan, Wei Meiling, waits long term toxicity test [J] Chinese Hospitals medicines of trichosanthes and allium macrostemon dropping pills
Learn magazine, 2015,35 (13):1172-1179.)
Pericarpium Trichosanthis extract and longstamen onion bulb extract are compounded, by Mutiple Targets, more significantly reduce blood lipid level, and have
Significant antioxidation activity.
With reference to Zhang Zhongjing《Synopsis Golden Chamber》In " Gualou Xiebai Baijiu Tang ", and combine natural drug reducing blood lipid regulation machine
System and combination principle, compatibility is carried out to PERICARPIUM TRICHOSANTHIS and longstamen onion bulb extract.Two kinds of natural drugs (extract) are according to certain ratio
Combination, develops the compound preparation of PERICARPIUM TRICHOSANTHIS ＆ Longstamen Onion Bulb reducing blood lipid, and the active component in extract reaches optimal drop by Mutiple Targets
Fat effect.
The content of the invention
It is an object of the invention to provide a kind of medicine or food, contain the blood lipid-lowering composite in the medicine or food
Thing.
To achieve these goals, the technical solution used in the present invention is：
A kind of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, it is active ingredient that the compound, which includes Pericarpium Trichosanthis extract and longstamen onion bulb extract,.
The ratio of PERICARPIUM TRICHOSANTHIS and Longstamen Onion Bulb raw material is 1:7.83-1:3.58.
The ratio 1 of adenosine in Quercetin and longstamen onion bulb extract in described Pericarpium Trichosanthis extract:8-1:4.Wherein Snakegourd Fruit
The content of general flavone is 5-6mg/g in bark extract, and the content of total polyphenols is 7-8mg/g, and the content of total saposins is 7-8mg/g,
The content of Quercetin is 0.1-0.2mg/g, and the content of adenosine is 0.07-0.08mg/g, and the content of total amino acid is 62-63mg/
g；The content of general flavone is 2-3mg/g in longstamen onion bulb extract, and the content of total polyphenols is 3-4mg/g, and the content of total saposins is 19-
20mg/g, the content of adenosine is 0.1-0.2mg/g, and the content of total amino acid is 26-27mg/g.
A kind of preparation method of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, comprises the following steps：
Step 1, PERICARPIUM TRICHOSANTHIS is weighed respectively, the dried powder of Longstamen Onion Bulb is placed in different Backflow bottles；
Step 2, the ethanol of 10 times of volumes 60% is separately added into, flowed back, filtering, collect filtrate；
Step 3, the residue in step 2 is added to 60% ethanol of 10 times of volumes, flowed back, filtering, collected and merge filter
Liquid；
Step 4, the product in step 3 is removed into ethanol and moisture with Rotary Evaporators, adds the pure of certain volume
Water, it is well mixed, it is 2.1g/mL crude drugs to be configured to concentration.
Return time is 2 hours in described step two and step 3.
Above-mentioned reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, it has antioxidation activity and reducing blood lipid bilayer effect.
Antioxidation activity effect of above-mentioned reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, shows as：Significantly rise serum and hepatic tissue SOD and
GSH-PX activity and reduction serum and Liver MDA.
The blood fat reducing function of above-mentioned reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, shows as：Significantly reduce serum TC, TG, LDL-C level.
Beneficial effects of the present invention：After Pericarpium Trichosanthis extract, longstamen onion bulb extract and PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extract compatibilities
Improve the blood lipid metabolism of hyperlipemia in mice, the PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extracts group of different proportion carries better than PERICARPIUM TRICHOSANTHIS is used alone
Take the effect of the regulation blood fat of thing or longstamen onion bulb extract.Illustrate that PERICARPIUM TRICHOSANTHIS plays cooperative effect with active component in Longstamen Onion Bulb, can be more preferable
Regulation blood fat, while the compound has significant antioxidation activity, and has repair function to liver, initiative.
Embodiment
The preparation of the compound of embodiment 1.
Pericarpium Trichosanthis extract and longstamen onion bulb extract are taken respectively, according to the different quality ratio (PERICARPIUM TRICHOSANTHIS listed by table 1：Longstamen Onion Bulb carries
Take thing) mixing, the pure water of certain volume is added, is well mixed, it is 2.1g/mL (crude drug volume) to be configured to concentration, prepares patent medicine
Thing compound group thing is standby.
The compound of table 1 forms
| PERICARPIUM TRICHOSANTHIS and Longstamen Onion Bulb raw material ratio | |
| 4 groups of Pericarpium Trichosanthis extract ＆ longstamen onion bulb extracts | 1:7.83 |
| 5 groups of Pericarpium Trichosanthis extract ＆ longstamen onion bulb extracts | 1:3.58 |
Embodiment 2. is anti-oxidant and hypolipidemic activity is tested
Experimental animal
C57BL/6 mouse, male, body weight 20g or so, 3-5w week old, cleaning grade are limited by Shanghai Si Laike experimental animals
Company is provided in Yancheng Health Vocational ＆ Technical College's animal center SPF levels Animal House raising, quality certification number：SCXK (Shanghai 2012-
0002)
Mouse feed
(feed is according to GB14924.3-2001 for basal feed《Experimental animal mouse rat mixed feed》Prepare), high fat is raised
Material is with reference to CFDA standard preparations.In order to prevent feed to be oxidized, preparation fresh feed per week, -20 DEG C of refrigerators are stored in.
Experiment material and instrument
Bezafibrate Tablet Jiangsu day Shi Libeite pharmaceutical Co. Ltds (Chinese medicines quasi-word：H20010013), peroxide disproportionation
Enzyme (SOD) kit, MDA (MDA) kit, glutathione peroxidase (GSH-PX) kit are purchased from Nanjing and built
Into research institute.Eclipse E100 microscope Japanese Nikons company.
Experimental procedure
Carry out packet administration according to table 2, food-intake is identical with drinking-water, is administered once daily in a manner of gavage, P1, P2, P3,
P4, P5, P6, P7 group gavage solution dosage are 0.2mL/10g/day [43] (equivalent to the 42g/kg/day of crude drug).After 75days
Blood is taken, it is standby to separate serum.
1. blood specimen collection：Medication is taken a blood sample after treating 75 days, low temperature 3000rpm collected after centrifugation serum, -80 DEG C of preservations, is used
Detected in blood biochemistry.Blood biochemistry Testing index has：Triglycerides (TG), T-CHOL (TC), low-density lipoprotein (LDL-C) and
HDL (HDL-C).
2. the measure of internal Antioxidant Indexes：Serum, liver organization detection superoxide dismutase, glutathione peroxidating
The activity and mda content of thing enzyme.With reference to the specification for building up research institute's offer, this reagent determines using hydroxylamine assay
SOD, GSH-Px vigor and MDA contents.
3. press sample collection：For anesthetized mice after Saline perfusion, dirty and blood vessel of coring is (total from the arch of aorta to kidney ilium
Artery), normal saline flushing, in the long 1cm aorta vessels of arch of aorta lower edge horizontal cutting, sustainer is soaked in 4% poly
Formaldehyde is fixed；Heart tissue is embedded in OCT, and -80 DEG C save backup；After the liver, heart and kidney of peeling off mouse, physiology salt is used
Crimson blood is removed in washing, then is blotted, weighed with filter paper, and liver device is soaked in into 4% paraformaldehyde fixes.
4. pathological observation：Sample liver will be fixed, heart efferent tract carries out FFPE, HE dyeing.
Table 2 is grouped and is administered
| Packet | Dosage |
| Control group | Conventional feed |
| High fat group | High lipid food |
| High fat+physiological saline | Same volume |
| High fat+Bezafibrate Tablet | 117mg/kg/d |
| High fat+P1 | Pericarpium Trichosanthis extract |
| High fat+P2 | Longstamen onion bulb extract |
| High fat+P3 | PERICARPIUM TRICHOSANTHIS ＆ Longstamen Onion Bulbs raw material 1:1.50 |
| High fat+P4 | PERICARPIUM TRICHOSANTHIS ＆ Longstamen Onion Bulbs raw material 1:7.83 |
| High fat+P5 | PERICARPIUM TRICHOSANTHIS ＆ Longstamen Onion Bulbs raw material 1:3.58 |
| High fat+P6 | PERICARPIUM TRICHOSANTHIS ＆ Longstamen Onion Bulbs raw material 2.10:1 |
| High fat+P7 | PERICARPIUM TRICHOSANTHIS ＆ Longstamen Onion Bulbs raw material 7.69:1 |
(1) result
1. model index determining
To be learnt by table 3, model group is fed after high lipid food continuously feeds 4 weeks, by compared with control group, serum triglyceride
Rise, serum total cholesterol and LDL-C rise, difference have conspicuousness, and decision model is set up.
Mouse index changes after table 3 models
(compared with conventional feed, * * represent P<0.01)
2. the influence to lipid of mice
As shown in Table 4, Pericarpium Trichosanthis extract, longstamen onion bulb extract, the compatibility of the different compounds of PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extracts are equal
Play the role of to adjust experimental hyperlipidemia lipid of mice, from the point of view of blood lipids index, Snakegourd Fruit ＆ longstamen onion bulb extract compound compatibility preparations
The effect of blood fat is adjusted better than exclusive use Pericarpium Trichosanthis extract or longstamen onion bulb extract.
The Pericarpium Trichosanthis extract of table 4, longstamen onion bulb extract and compound group on lipid of mice influence (n=10,)mmol/L
(note:A is P>0.05, b 0.05>P >=0.01, c P<0.01)
3. on oxidation resistant influence in Mice Body
SOD activity, GSH-PX activity and MDA contents in each group mice serum of table 5, tissue
(note:A is p>0.05, b 0.05>P >=0.01, c p<0.01)
SOD in i difference groups serum, tissue sample is for example as shown in table 5, and physiological saline and high fat group are poor without conspicuousness
It is different, illustrate that gavage does not influence on SOD.SOD in high fat group mice serum is less than conventional feed group, but there was no significant difference.
Compared to Pericarpium Trichosanthis extract group P1, longstamen onion bulb extract group P2, the SOD in PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extract compound groups except P3 groups drops
Low, other have rise, and wherein P4 groups, P5 groups, P6 groups and P7 groups raises 1.75%, 6.56%, 5.52%, 12.87% respectively.
P7 group SOD value highests, and have significant difference, SOD rises 13.20% with high fat group.
The low conventional feed groups of SOD in high fat group murine liver tissue, and have significant difference.Other each groups SOD values are high
In in high fat group, except P3 groups, there was no significant difference, the higher fat group rise of higher fat group rise 7.52%, the P1 groups of Bezafibrate group
The higher fat group rise 27.82% of higher fat group rise 2.26%, the P4 groups of higher fat group rise 7.52%, the P3 groups of 5.26%, P2 group,
The higher fat group rise 12.78% of higher fat group rise 8.27%, the P7 groups of higher fat group rise 18.05%, the P6 groups of P5 groups, Snakegourd Fruit
The SOD values of skin ＆ longstamen onion bulb extract compound groups are above Pericarpium Trichosanthis extract group P1, longstamen onion bulb extract group P2, wherein P4 groups SOD values
Highest.
GSH-PX in ii difference groups serum, tissue sample is for example as shown in table 5, and physiological saline is with high fat group without conspicuousness
Difference, illustrate that gavage does not influence on GSH-PX.GSH-PX in high fat group mice serum is less than conventional feed group, but without notable
Sex differernce.Compared with high fat group, Bezafibrate group, P1 groups, P2 group P3 groups, P4 groups, P5 groups, P6 groups and P7 groups raise respectively
50.92%th, 10.93%, 9.20%, 39.89%, 91.41%, 117.18%, 19.63%, 23.31%, wherein P5 groups and height
Fat group has significant difference.The GSH-PX values of PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extract compound groups are above Pericarpium Trichosanthis extract group P1, Longstamen Onion Bulb
Extract group P2, wherein P5 groups GSH-PX highests.
GSH-PX in high fat group murine liver tissue is less than conventional feed group, and has significant difference.Compared with high fat group
Bezafibrate group, P1 groups, P2 groups, P3 groups, P4 groups, P5 groups, P6 groups and P7 groups raise 36.81% respectively, 1.49%, 24.04%,
28.70%th, 14.07%, 33.64%, 7.74%, wherein Bezafibrate group, P2 groups, P3 groups, P4 groups and P6 groups is deposited with high fat group
Significant difference.The P3 groups of PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extract compound groups and the GSH-PX values of P6 groups are above Pericarpium Trichosanthis extract group
P1, wherein longstamen onion bulb extract group P2, P6 groups GSH-PX highests but it is less than Bezafibrate group.
MDA in iii difference groups serum, tissue sample is as shown in table 5, and physiological saline and high fat group are poor without conspicuousness
It is different, illustrate that gavage does not influence on MDA.MDA in high fat group mice serum is higher than conventional feed group, and it is poor conspicuousness to be present
It is different.Compared with high fat group Bezafibrate group, P1 groups, P2 groups, P4 groups, P5 groups, P6 groups and P7 groups reduce 38.52% respectively,
9.02%th, 7.38%, 17.21%, 24.59%, 18.03%, 27.04%, P3 groups rise 13.11%.Bezafibrate group, P4
Significant difference be present with high fat group in group, P5 groups and P7 groups.The P4 groups of PERICARPIUM TRICHOSANTHIS ＆ longstamen onion bulb extract compound groups, P5 groups, P6 groups and
The MDA values of P7 groups are below in Pericarpium Trichosanthis extract group P1, and longstamen onion bulb extract group P2, wherein P7 groups MDA are minimum, and P5 groups are taken second place.
MDA in high fat group mouse tissue is less than conventional feed group, and other each groups are less than high fat group except P6 groups MDA, and other are all higher than height
Fat group, this may be relevant with the impurity in tissue.P6 groups reduce by 33.98%.
4. to liver and sustainer pathological observation result
Hyperlipemia mouse liver histopathology microscope (20 ×) is observed, high fat group mouse liver, lobuli hepatis structure
Owe clear, the liver cell fat that mouse has moderate to severe becomes disease, and fatty bubble of different sizes, liver are presented in endochylema
Cell volume, which becomes, to be rounded greatly, and nucleus is pressed against on one side, and shape changes, and sinus hepaticus significantly narrows or disappeared, liver cell
Dyeing it is more shallow than normal cell, endochylema light dye in acinus to be presented point-like or focal necrosis more, portal area in, it is slight
Inflammatory cell infiltration, do not find significant liver fibrosis, most of central veins of hepatic lobules nearby cholesterol crystal occurs, often
It is stable to advise feed group mouse liver institutional framework, liver rope is arranged centered on central vein into radial to surrounding, lobuli hepatis wheel
Wide clearly demarcated, polygon is presented in liver cell, and cell boundaries are clearly demarcated, and core is round and clear, occupy among cell, a large amount of kytoplasms；Benzene pricks shellfish
Spy's group mouse liver eucaryotic cell structure is complete, and cell hydropic degeneration disappears, and bubble is reduced, and liver cell coloring is deepened；P1-P7 group mouse
Liver is slightly taken a turn for the better, and wherein P4 groups are best, and P5 groups are taken second place.
Hyperlipemia mouse angiological pathology microscope (40 ×) is observed, and high fat group mouse vascellum tunica interna incrassation, protuberance, is had
Part endothelial cell decline, subendothelial space become big, and inner membrance has oedema phenomenon, has foam to penetrate into cell, and smooth muscle cell is inside
Subcutaneous metastasis, middle film is substantially thicker, and smooth muscle cell occurs increasing and irregularly then turns to inner membrance perpendicular to inner membrance, organizes shape
State produce change, conventional feed mouse blood vessel is clear, and inner membrance is smooth, endothelial cell Stability Analysis of Structures, it is subendothelial be not present lipid and
Inflammatory cell infiltration, middle level and outer membrane structure understand that middle film layer is made up of elastic fibers film, existing crowd between elastic fibers film
More prismatic core smooth muscle cells and a small number of fibre fractionations, outer membrane is relatively thin, adipocyte does not occur；Bezafibrate group blood vessel structure
State to rebuild shield, level than more visible, inner membrance smoother and endothelial cell morphology it is continuously intact；P1-P7 groups are
Improve.
Claims (9)
- A kind of 1. reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, it is characterised in that：The compound includes Pericarpium Trichosanthis extract and longstamen onion bulb extract to have Imitate composition.
- 2. a kind of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound according to claim 1, the wherein Pericarpium Trichosanthis extract in compound can pass through IR finger-prints are differentiated, collection of illustrative plates appearance scope：533.80~3415.61cm-1.
- 3. a kind of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound according to claim 1, the wherein longstamen onion bulb extract in compound can pass through IR Finger-print differentiated, collection of illustrative plates appearance scope：597.55~3489.77cm-1.
- A kind of 4. reducing blood lipid PERICARPIUM TRICHOSANTHIS compound according to claim 1, it is characterised in that：The ratio of PERICARPIUM TRICHOSANTHIS and Longstamen Onion Bulb raw material Example is 1:7.83-1:3.58.
- A kind of 5. reducing blood lipid PERICARPIUM TRICHOSANTHIS compound according to claim 1, it is characterised in that：In described Pericarpium Trichosanthis extract Quercetin and longstamen onion bulb extract in adenosine ratio 1:8-1:4.
- A kind of 6. reducing blood lipid PERICARPIUM TRICHOSANTHIS compound according to claim 1, it is characterised in that：It is total wherein in Pericarpium Trichosanthis extract The content of flavones is 5-6mg/g, and the contents of total polyphenols is 7-8mg/g, and the contents of total saposins is 7-8mg/g, the content of Quercetin For 0.1-0.2mg/g, the content of adenosine is 0.07-0.08mg/g, and the content of total amino acid is 62-63mg/g；Longstamen onion bulb extract The content of middle general flavone is 2-3mg/g, and the content of total polyphenols is 3-4mg/g, and the content of total saposins is 19-20mg/g, adenosine Content is 0.1-0.2mg/g, and the content of total amino acid is 26-27mg/g.
- 7. a kind of preparation method of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound, it is characterised in that comprise the following steps：Step 1, PERICARPIUM TRICHOSANTHIS is weighed respectively, the dried powder of Longstamen Onion Bulb is placed in different Backflow bottles；Step 2, the ethanol of 10 times of volumes 60% is separately added into, flowed back, filtering, collect filtrate；Step 3, the residue in step 2 is added to 60% ethanol of 10 times of volumes, flowed back, filtering, collect merging filtrate；Step 4, the product in step 3 is removed into ethanol and moisture with Rotary Evaporators, the pure water of certain volume is added, mixes Close uniformly, it is 2.1g/mL crude drugs to be configured to concentration.
- A kind of 8. preparation method of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound according to claim 7, it is characterised in that described step Return time is 2 hours in two.
- A kind of 9. preparation method of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound according to claim 7, it is characterised in that described step Return time is 2 hours in three.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710604800.8A CN107349318B (en) | 2017-07-25 | 2017-07-25 | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710604800.8A CN107349318B (en) | 2017-07-25 | 2017-07-25 | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107349318A true CN107349318A (en) | 2017-11-17 |
| CN107349318B CN107349318B (en) | 2020-11-20 |
Family
ID=60284806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710604800.8A Expired - Fee Related CN107349318B (en) | 2017-07-25 | 2017-07-25 | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107349318B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280851A (en) * | 1999-07-15 | 2001-01-24 | 沈阳药科大学 | Chinese-medicinal composition containing Chinese onion for improving hyperlipomia |
| CN1486707A (en) * | 2002-09-30 | 2004-04-07 | 吉林省东方制药有限公司 | Method of extracting medicine for hyperlipemia from Chinese onion bulb |
| CN1927329A (en) * | 2006-09-11 | 2007-03-14 | 天津大学 | Medicine for curing cardiovascular disease and its preparation method |
| CN101224274A (en) * | 2008-01-10 | 2008-07-23 | 江苏吴中苏药医药开发有限责任公司 | Medicine compounds of pericarp trichosanthis, longstamen onion bulb extract and preparing method thereof |
| CN102058757A (en) * | 2010-11-25 | 2011-05-18 | 代龙 | Traditional Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof |
-
2017
- 2017-07-25 CN CN201710604800.8A patent/CN107349318B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280851A (en) * | 1999-07-15 | 2001-01-24 | 沈阳药科大学 | Chinese-medicinal composition containing Chinese onion for improving hyperlipomia |
| CN1486707A (en) * | 2002-09-30 | 2004-04-07 | 吉林省东方制药有限公司 | Method of extracting medicine for hyperlipemia from Chinese onion bulb |
| CN1927329A (en) * | 2006-09-11 | 2007-03-14 | 天津大学 | Medicine for curing cardiovascular disease and its preparation method |
| CN101224274A (en) * | 2008-01-10 | 2008-07-23 | 江苏吴中苏药医药开发有限责任公司 | Medicine compounds of pericarp trichosanthis, longstamen onion bulb extract and preparing method thereof |
| CN102058757A (en) * | 2010-11-25 | 2011-05-18 | 代龙 | Traditional Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 杨丽等: "瓜蒌皮与薤白提取物中主要物质含量测定条件的优化", 《食品工业》 * |
| 范颖等: "《中药药对配方理论及应用》", 31 October 2015, 辽宁科学技术出版社 * |
| 贺立勍: "瓜蒌、薤白降脂作用的析因研究", 《湖南中医药导报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107349318B (en) | 2020-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nair et al. | Evaluation of in vitro antidiabetic activity of selected plant extracts | |
| Savina et al. | Chemical composition and toxicological evaluation of the aqueous leaf extracts of Plectranthus amboinicus Lour. Spreng | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| Chen et al. | A 90-day subchronic toxicity study of submerged mycelial culture of Cordyceps cicadae (ascomycetes) in rats | |
| CN106798762A (en) | One Plant Extracts and its preparation method and application | |
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| Sarkar et al. | Evaluation of in vitro anti diabetic activity of two mangrove plant extracts: Heritiera fomes and Sonneratia apetala | |
| CN105025910A (en) | Pharmaceutical composition and functional food for prevention or treatment of diabetic complications or angioedema comprising natural extract | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN108567914A (en) | It is a kind of that there is the Chinese medicine preparation and its preparation method and application for improving sleep effect | |
| CN107349318A (en) | A kind of reducing blood lipid PERICARPIUM TRICHOSANTHIS compound and preparation method thereof | |
| CN103908571A (en) | Compound traditional Chinese medicine preparation for treating heart disease | |
| CN102430001B (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN105726624A (en) | Pharmaceutical composition for treating diabetes | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| CN104510884A (en) | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product | |
| CN103816392B (en) | Pharmaceutical composition of a kind for the treatment of organs fibrosis and its production and use | |
| CN100336526C (en) | Medicine composition for treating diabetes and preparing method | |
| Obarisiagbon et al. | STUDIES ON THE EFFECTS OF VERNONIA AMYGDALINA AQUEOUS LEAF EXTRACT ON THE BIOCHEMICAL, HAEMATOLOGICAL AND HYPOGLYCEMIC PARAMETERS IN DIABETIC RATS: PREREQUISITE TO FORMULATION INTO PHARMACEUTICAL DOSAGE FORM. | |
| CN106492008B (en) | Traditional Chinese medicine formula for preparing product for resisting diabetic nephropathy and preparation method and application thereof | |
| EA035673B1 (en) | Mixture for treating pathologies associated with lymphatic hyperpermeability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201120 Termination date: 20210725 |